2, 5, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-3-YLAMINES OR 2, 3, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-5-YLAMINES Russian patent published in 2015 - IPC C07D413/12 C07D417/12 A61K31/553 A61P25/28 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to formula

compounds, possessing properties of BACE1 (enzyme 1, cleaving β-site of protein-precursor of β-amyloid) and/or BACE2 inhibitors, and their pharmaceutically acceptable salts, as well as to based on them pharmaceutical composition, their application and method of therapeutic and/or preventive impact on such diseases as Alzheimer's disease, type 2 diabetes. In general formula (I) A represents O, and B represents -CR⁸R⁹-; or B represents O and A represents -CR⁸R⁹-; R¹ is selected from hydrogen and C_1-7-alkyl; R² is selected from hydrogen and C_1-7-alkyl; R³ is selected from hydrogen and halogen; R⁴ is selected from hydrogen and halogen; R⁵ represents C_1-7-alkyl; or R³ and R⁵ together with C atom, which they are bound to, form cyclopropyl ring; R^6a, R^6b, R^6c and R^6d are selected from hydrogen and halogen; R⁷ represents -(CO)-R¹⁰ or R¹¹, where R¹⁰ is selected from the group, consisting of 5-6-membered heteroaryl with 1-3 heteroatoms, selected from N, O and S, with said heteroaryl being non-substituted or substituted with one-two groups, selected from the group, consisting of C_1-7-alkyl, halogen, halogen-C_1-7-alkyl, C_1-7-alkoxy, halogen-C_1-7-alkoxy, cyano, -COO-CH₂-CH₃, halogen-C_1-7-alkyl, C_3-7-cycloalkyl, with said cycloalkyl being non-substituted or substituted with one-four groups, selected from C_1-7-alkyl, halogen or halogen-C_1-7-alkyl, and C_1-7-alkoxy-C_1-7-alkyl, R¹¹ is selected from C_1-7-alkyl and C_3-7-cycloalkyl; R⁸ and R⁹ independently on each other are selected from hydrogen, C_1-7-alkyl and phenyl.

EFFECT: obtaining medication for therapeutic and/or preventive impact on such diseases as Alzheimer's disease, type 2 diabetes.

25 cl, 7 tbl, 118 ex